当前位置: 首页 >> 检索结果
142. PCK1 deficiency promotes MASH-HCC progression by 12-HETE-induced CD8+ T cell dysfunction.
作者: Kang Wu.;Luo Li.;Yi Liu.;Kai Wang.;Jianghong Zheng.;Huijun Liang.;Fengli Xu.;Renming Liu.;Chang Chen.;Luyi Huang.;Haijun Deng.;Xiaojian Han.;Shi Chen.;Zhirong Zhang.;Xinyu Liu.;Qiang He.;Xiaosong Li.;Aishun Jin.;Ailong Huang.;Ni Tang.
来源: Gut. 2025年
Metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma (MASH-HCC) has been reported to be less responsive to immune checkpoint inhibitors, which may be associated with metabolic reprogramming of tumour cells and abnormal tumour microenvironment.
143. "DPP- 4 inhibitor alleviates gut-brain axis Parkinson's disease pathology" - can dipeptidyl peptidase 4 inhibitors be repurposed as disease-modifying drugs for body-first Parkinson's disease patients?144. CD177+ neutrophils drive extracellular matrix remodelling and HGF-alpha release in ALPPS-induced liver regeneration.
作者: Jiayan Yan.;Ao Huang.;Shiyu Zhang.;Na Yao.;Junfeng Huang.;Zhifeng Jiang.;Jiayi Wang.;Feiyu Chen.;Qichao Yu.;Jianwen Cheng.;Senquan Zhang.;Tianyi Li.;Rongshan Gao.;Runze Miao.;Rongkui Luo.;Shaolai Zhou.;Yuan Ji.;Zheng Wang.;Dongmei Gao.;Zhenbin Ding.;Zhaoyou Tang.;Jia Fan.;Miguel A Esteban.;Hans Jürgen Schlitt.;Xinrong Yang.;Jian Zhou.
来源: Gut. 2025年
Associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) effectively induces rapid liver hypertrophy in patients with initially unresectable liver tumours, yet the immunological mechanisms remain unclear.
145. Fibroblast pentose phosphate pathway activation upon decreased circPLCE1 exacerbates intestinal fibrosis in Crohn's disease.
作者: Longyuan Zhou.;Jing Nie.;Zhiyin Feng.;Rongchang Li.;Pingxin Zhang.;Sinan Lin.;Yao Zhang.;Florian Rieder.;Changhao Chen.;Minhu Chen.;Ren Mao.
来源: Gut. 2025年
Intestinal fibrosis, a hallmark complication of Crohn's disease (CD), frequently progresses to stricture formation and surgical intervention. Fibroblast metabolic reprogramming is important in organ fibrosis. However, its role in intestinal fibrogenesis of CD remains elusive.
146. Spatial transcriptomics defines the molecular progression, invasion and immune landscape of IPMN and IPMN-derived pancreatic cancer.
作者: Ming Cui.;Shengwei Mo.;Jialu Bai.;Ammar A Javed.;Joseph R Habib.;Sen Yang.;Tianqi Chen.;Ruiling Xiao.;Wenfei Diao.;Decheng Jiang.;Christopher L Wolfgang.;Xiaoyan Chang.;Ya Hu.;Yupei Zhao.
来源: Gut. 2026年75卷4期801-814页
Intraductal papillary mucinous neoplasms (IPMNs) are precursor lesions of pancreatic cancer with highly variable malignant potential. Current understanding of their biology remains incomplete, limiting accurate risk stratification and targeted interventions.
147. Preclinical stages of Crohn's disease defined by faecal calprotectin in asymptomatic first-degree relatives: screening framework for prevention trials.
作者: Dan Turner.;Sarah Kenigsberg.;Gili Focht.;Williams Turpin.;Oren Ledder.;Anne M Griffiths.;Hien Q Huynh.;Luba Plotkin.;Yonat Aharoni-Frutkoff.;Wael El-Matary.;Anthony R Otley.;Irit Avni-Biron.;Kevan Jacobson.;Remo Panaccione.;Joana Torres.;Sun-Ho Lee.;Kenneth Croitoru.
来源: Gut. 2026年
The PIONIR (Preventing IBD ONset in Individuals at Risk) trial evaluates whether the Tasty&Healthy diet can reduce risk of Crohn's disease (CD) development in first-degree relatives (FDRs). The optimal preclinical stage of CD for enrolling subjects to prevention trials is unknown.
152. Autophagy of Kupffer cells modulates CD8+ T cell activation in primary biliary cholangitis.
作者: Pan-Yue Luo.;Min Ma.;Meng-Chu Liu.;Ye-Hui Wu.;Jie Long.;Meng-Xing Huang.;Si-Yu Yang.;Tian-Tian Da.;Koichi Tsuneyama.;Qiao Li.;Haosheng Jin.;Zhi-Bin Zhao.;Jun Wang.;Xiong Ma.;Merrill Eric Gershwin.;Ying Han.;Zhe-Xiong Lian.;Liang Li.
来源: Gut. 2025年
Kupffer cells and monocyte-derived macrophages (MoMs) are difficult to study in human primary biliary cholangitis (PBC) even though they reflect a dynamic hepatic immune population.
154. Stem-like CD8+ T cells preserve HBV-specific responses in HBV/HIV co-infection.
作者: Anucha Preechanukul.;Aljawharah Alrubayyi.;Bo Sun.;Edward Arbe-Barnes.;Jonida Kokici.;Frances Gorou.;Sarun Prasitdumrong.;Kelly A S da Costa.;Natasha Fisher-Pearson.;Noshin Hussain.;Stephanie Kucykowicz.;Indrajit Ghosh.;Fiona Burns.;Sabine Kinloch.;Pedro Simoes.;Sanjay Bhagani.;Patrick T F Kennedy.;Mala K Maini.;Rachael Bashford-Rogers.;Upkar S Gill.;Dimitra Peppa.
来源: Gut. 2025年
Chronic hepatitis B virus (HBV) infection disproportionately affects people living with HIV, who are often excluded from functional cure studies.
158. Gut microbe alleviates stress-related cancer metastasis by oleic acid degradation.
作者: Chen Liu.;Junli Gong.;Zhanhao Luo.;Peng Lai.;Shuang Guo.;Dayi Liang.;Guangyuan Chen.;Mengze Xing.;Jing Yu.;Yanchun Xie.;Danling Liu.;Wanyi Zeng.;Zhen He.;Ping Lan.
来源: Gut. 2025年
Chronic stress is a known risk factor for cancer metastasis. However, the underlying mechanisms, particularly those involving the gut microbiota and their metabolites, remain unclear.
159. Intraperitoneal translocation of gut microbiota induces NETosis and promotes endometriosis.
作者: Xiangguang Wu.;Mingfu Wu.;Huawen Li.;Yang Yang.;Huimin Shen.;Siyuan Huang.;Yuha Pan.;Liwen Tao.;Shuangshuang Guo.;Jinjiao Chen.;Yu Wu.;Xiaoqing Zhong.;Shuangdi Li.;Binya Liu.;Wenliang Zhang.;Ruixin Zhu.;Liangsheng Fan.;Wei Wang.
来源: Gut. 2025年
Endometriosis is a debilitating gynaecological disorder with an elusive pathogenesis. While gut microbiota dysbiosis has been implicated, the causal role of gut-peritoneum microbial translocation and the specific mechanisms driving disease progression remain elusive. Notably, the role of peritoneal neutrophils and neutrophil extracellular traps (NETs) in the development of endometriosis remains unknown.
160. Decoding HBV-specific adaptive immunity: from natural clearance to cure.
Chronic HBV infection remains a major global health burden, with current antiviral therapies effectively suppressing viral replication but rarely achieving functional cure. Adaptive immunity is central to viral clearance but is profoundly impaired during chronic infection. Inducing and enhancing adaptive immunity through therapeutic vaccines, immune checkpoint inhibitors or T cell-based therapies represents a promising approach for HBV cure strategies. However, recent preclinical and clinical studies have demonstrated only limited efficacy, underscoring major immunological challenges. In this review, we summarise current knowledge of the correlates of viral clearance and persistence, discuss key unresolved questions and outline future research directions needed to advance immune-based HBV cure strategies.
|